Office PoliticsI've Always Wondered ...Election 2024Adventures in Housing

Loading...

0:00
0% played
We fell short of our Fall Fundraiser goal of 2,500 donations. Help us catch up ⏩ Give Now

Dan Gorenstein

Senior Reporter

SHORT BIO

Dan Gorenstein is the former senior reporter for Marketplace’s Health Desk, covering the business of healthcare.

Prior to Marketplace, Dan spent more than 11 years at New Hampshire Public Radio. He got his start in journalism at the Chicago Reporter, an investigative journal that examines race and class disparities in the Chicago area. He’s won numerous national and local awards, including the Society of Professional Journalist Sigma Delta Chi investigative reporting award.

Latest Stories (640)

The only way to stop inversions might be tax reform

by Dan Gorenstein
Apr 6, 2016
The Pfizer-Allergan merger is out, but what about inversions across the board?
Pfizer was set to merge with Allergan, but after new inversion rules announced by the Treasury Department, the phama giants decided against merging. 
Spencer Platt/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE
Secretary of the Future

The future of hospital care could look a lot like home

by Dan Gorenstein
Apr 5, 2016
A growing body of research suggests the "hospital-at-home" model leads to better quality care.
The "hospital-at-home" model may lead to better quality care for patients, according to research.
Carsten/Three Lions/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

FTC fights against new strategy for delaying generics

by Dan Gorenstein
Apr 1, 2016
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
John Moore/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE

Hospitals could be doing more to prevent cyber attacks

by Dan Gorenstein
Mar 29, 2016
Expert says too often hospitals beef up security after an attack.
A patient lies in his hospital room with an EKG on a bedside workstation at the Indiana Heart Hospital.
Mike Simons/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Zika virus prevention efforts in the U.S. underway

by Dan Gorenstein
Mar 29, 2016
The president has asked Congress for nearly $2 billion in emergency funding.
Health workers in Brazil fumigate in an attempt to eradicate the mosquito which transmits the Zika virus. In the U.S., the Centers for Disease Control and Prevention are trying to organize efforts to combat the virus. 
Mario Tama/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant's story: a cautionary tale

by Dan Gorenstein
Mar 21, 2016
The company's CEO stepped down on Monday
Howard Schiller, then interim CEO of Valeant Pharmaceuticals International, Inc., listens during a hearing of the House Oversight and Government Reform Committee on Capitol Hill February 4, 2016 in Washington, DC. 
BRENDAN SMIALOWSKI/AFP/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Hospital mergers within state borders drive up costs

by Dan Gorenstein
Mar 21, 2016
And nobody is watching.
Employers and consumers tend to get hurt by hospital cross-market mergers, according to a new study. 
valelopardo/pixabay
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Health care tax inversions allow double dipping, according to new report

by Dan Gorenstein
Mar 17, 2016
Companies sidestep taxes that support Medicare or Medicaid, then sell those programs drugs.
Mergers with foreign-based companies can help some U.S. companies avoid taxes. 
Mario Tama/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

FDA takes step to improve generic drug competition

by Dan Gorenstein
Mar 15, 2016
We'd pay a lot more if it wasn’t for generics, which amount to as much as 85% of what we take.
Joe Raedle/Getty Images
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE

Valeant swears off aggressive drug pricing strategy

by Dan Gorenstein
Mar 15, 2016
Valeant and a handful other firms may ditch a model that's come under fire.
Valeant and a handful other firms may ditch a model that's come under fire.
Image via Life Science Association of Manitoba/YouTube
ListenLISTEN
HTML EMBED:
COPY
EMBED EMBED
Share Now on:
SHARE
Subscribe Using:
SUBSCRIBE SUBSCRIBE